Treatment of three different patient‐derived GBM cell models (GBM10, GBM34, GBM146) and the glioma cell line U87MG with human recombinant CTRP8 consistently resulted in a 40–50% upregulation of Cdc42 protein. Here, CDC42 is linked to central nervous system cancer.